Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

被引：0
|
作者：
A. Rivero-Juarez
J. A. Mira
A. Camacho
K. Neukam
I. Perez-Camacho
A. Caruz
J. Macias
J. Torre-Cisneros
J. A. Pineda
A. Rivero
机构：
[1] Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC),Unidad de Enfermedades Infecciosas
[2] Hospital Universitario Reina Sofia,Unidad de Enfermedades Infecciosas
[3] Hospital Universitario Virgen de Valme,Departamento de Biología Molecular
[4] Hospital de Poniente,undefined
[5] Universidad de Jaen,undefined
来源：
Infection | 2013年 / 41卷
关键词：
HCV; HIV; End-of-treatment response; Viral relapse; Risk factors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：21 / 26
页数：5
相关论文
共 50 条
  • [1] Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV
    Rivero-Juarez, A.
    Mira, J. A.
    Camacho, A.
    Neukam, K.
    Perez-Camacho, I.
    Caruz, A.
    Macias, J.
    Torre-Cisneros, J.
    Pineda, J. A.
    Rivero, A.
    INFECTION, 2013, 41 (01) : 21 - 26
  • [2] Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients
    Donato, C.
    Cingolani, A.
    Pinnetti, C.
    De Luca, A.
    JOURNAL OF HEPATOLOGY, 2010, 52 (02) : 306 - 307
  • [3] Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy
    Yasuteru Kondo
    Yoshiyuki Ueno
    Masashi Ninomiya
    Keiichi Tamai
    Yasuhito Tanaka
    Jun Inoue
    Eiji Kakazu
    Koju Kobayashi
    Osamu Kimura
    Masahito Miura
    Takeshi Yamamoto
    Tomoo Kobayashi
    Takehiko Igarashi
    Tooru Shimosegawa
    Journal of Gastroenterology, 2012, 47 : 1323 - 1335
  • [4] Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy
    Kondo, Yasuteru
    Ueno, Yoshiyuki
    Ninomiya, Masashi
    Tamai, Keiichi
    Tanaka, Yasuhito
    Inoue, Jun
    Kakazu, Eiji
    Kobayashi, Koju
    Kimura, Osamu
    Miura, Masahito
    Yamamoto, Takeshi
    Kobayashi, Tomoo
    Igarashi, Takehiko
    Shimosegawa, Tooru
    JOURNAL OF GASTROENTEROLOGY, 2012, 47 (12) : 1323 - 1335
  • [5] Early virological response in HIV/HCV co-infected patients to IFN or Peg-IFN plus ribavirin assessed by HCV RNA measurement
    Payan, C.
    Pivert, A.
    Morand, P.
    Fafi-Kremer, S.
    Carrat, F.
    Pol, S.
    Cacoub, P.
    Perronne, C.
    Lunel, F.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S134 - S134
  • [6] An open, multicenter, randomized trial comparing pegylated interferon alpha-2b (PEG-IFN) plus ribavirin (RBV) versus PEG-IFN for treatment of HIV/HCV co-infected patients.
    Cargnel, A
    Angeli, E
    Casella, A
    Gubertini, G
    Mainini, A
    Orlando, G
    Duca, P
    HEPATOLOGY, 2002, 36 (04) : 363A - 363A
  • [7] Prevalence of risk factors for HCV transmission in HIV infected and HIV/HCV co-infected patients
    Bollepalli, S
    Mahthieson, K
    Post, J
    Hillier, A
    Nadir, A
    HEPATOLOGY, 2005, 42 (04) : 423A - 423A
  • [8] Pegylated interferon alfa-2b (PEG-IFN) plus ribavirin versus PEG-IFN for treatment of HIV/HCV co-infected patients (pts): An open, multicenter, randomized trial
    Cargnel, A
    Casella, A
    Angeli, E
    Gubertini, G
    Orlando, G
    Duca, P
    GASTROENTEROLOGY, 2002, 122 (04) : A630 - A630
  • [9] PHARMACODYNAMICS OF PEG-IFN ALPHA-2A AND HCV RESPONSE AS A FUNCTION OF IL28B POLYMORPHISM IN HIV/HCV CO-INFECTED PATIENTS
    Araujo, Evaldo S.
    Dahari, Harel
    Cotler, Scott J.
    Layden, Thomas J.
    Neumann, Avidan U.
    Melo, Carlos E.
    Barone, Antonio A.
    HEPATOLOGY, 2010, 52 (04) : 750A - 750A
  • [10] Treatment of HCV infected patients, including non-responders to PEG-IFN alfa2b/RBV, with PEG-IFN alfa2a/RBV: The Johns Hopkins experience
    Zeng, N
    Cohen, CK
    Schwartz, P
    Rai, R
    GASTROENTEROLOGY, 2004, 126 (04) : A722 - A722
12345